Tezacaftor / ivacaftor vs Vanzacaftor / tezacaftor / deutivacaftor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Cystic Fibrosis
Shared mechanism: CFTR · full Cystic Fibrosis pipeline
Tezacaftor / ivacaftor · Symdeko
Marketed by Vertex Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT03587961 (registry estimate)
No aligned efficacy figure on record for this race.
Vanzacaftor / tezacaftor / deutivacaftor · Alyftrek
Marketed by Vertex Pharmaceuticals
NCT05033080 · Phase 3 · completed
This was a randomized, quadruple-blind trial in 398 treated patients comparing the new combination against the active standard-of-care regimen. The primary endpoint, lung function (ppFEV1) at 24 weeks, met the pre-specified non-inferiority criterion (p<0.0001), with the new combination numerically matching or slightly exceeding the comparator (difference +0.2 percentage points, 95% CI -0.7 to 1.1).
Next expected readout: July 2029 · NCT05844449 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Cystic Fibrosis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Tezacaftor / ivacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.
Vanzacaftor / tezacaftor / deutivacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tezacaftor / ivacaftor's landscape · Vanzacaftor / tezacaftor / deutivacaftor's landscape